News Research Research and Publications

Study shows novel low-dose 3-in-1 blood pressure pill outperforms standard care

Over 80% of patients achieved control within a month, sustained at six months

A new study, that Mark Huffman, MD, MPH, William Bowen Professor of Medicine, Co-Director, Global Health Center, WashU Cardiovascular Division, who is a co-author, shows that a treatment plan containing low doses of three antihypertensive drugs in a single pill – known as GMRx2 – reduced blood pressure better than a high-quality standard treatment plan in patients with uncontrolled hypertension.

Results of the ‘deliVERy of Optimal blood pressure coNtrol in afrICA (VERONICA)-Nigeria’ trial, led by The George Institute for Global Health, were presented today at the European Society of Cardiology Congress 2024 and simultaneously published in the Journal of the American Medical Association (JAMA).

Mark Huffman
Huffman

I look forward to incorporating the findings from this trial into our ongoing NIH-funded program to integrate hypertension services into routine care throughout Nigeria in close collaboration with Prof. Dike Ojji at the University of Abuja (R01HL144708).

The clinical trial showed about 6 mm Hg greater lowering in systolic blood pressure, measured at home, in the intervention arm with similar tolerability between groups. The lead author on this JAMA study is Dr. Dike Ojji, from the University of Abuja, and the senior author is Dr. Anthony Rodgers, from The George Institute for Global Health.

The VERONICA trial is funded by the Australian National Health and Medical Research Council.

Read the official press release issued by The George Institute for Global Health.